Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

• Limin Zou,
• Yueli Qi,
• Yongling Jiang,
• Ling Tang,
• Yu Du,
• Boyuan Zhao,
• Yanzhe Sun,
• Meiyi Xiang,
• Jun Ma,
• Zhimin Yang

Affiliations

Limin Zou

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Yueli Qi

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Yongling Jiang

Office of Management and Communication, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Ling Tang

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Yu Du

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Boyuan Zhao

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Yanzhe Sun

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Meiyi Xiang

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China

Jun Ma

Harbin Institute of Hematology and Oncology Harbin 150010 Heilongjiang P. R. China

Zhimin Yang

Office of Clinical Evaluation 1, Center for Drug Evaluation National Medical Products Administration Beijing 100022 P. R. China